Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [2]
- Immunocytochemistry [1]
- Other assay [8]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 39-3400 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CDKN2C Monoclonal Antibody (ZP001)
- Antibody type
- Monoclonal
- Antigen
- Recombinant full-length protein
- Reactivity
- Human, Mouse
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- ZP001
- Vial size
- 100 µg
- Concentration
- 0.5 mg/mL
- Storage
- -20°C
Submitted references Differential expression of cell cycle regulators in CDK5-dependent medullary thyroid carcinoma tumorigenesis.
Estradiol partially recapitulates murine pituitary cell cycle response to pregnancy.
Differential post-transcriptional regulation of two Ink4 proteins, p18 Ink4c and p19 Ink4d.
EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice.
Pozo K, Hillmann A, Augustyn A, Plattner F, Hai T, Singh T, Ramezani S, Sun X, Pfragner R, Minna JD, Cote GJ, Chen H, Bibb JA, Nwariaku FE
Oncotarget 2015 May 20;6(14):12080-93
Oncotarget 2015 May 20;6(14):12080-93
Estradiol partially recapitulates murine pituitary cell cycle response to pregnancy.
Toledano Y, Zonis S, Ren SG, Wawrowsky K, Chesnokova V, Melmed S
Endocrinology 2012 Oct;153(10):5011-22
Endocrinology 2012 Oct;153(10):5011-22
Differential post-transcriptional regulation of two Ink4 proteins, p18 Ink4c and p19 Ink4d.
Forget A, Ayrault O, den Besten W, Kuo ML, Sherr CJ, Roussel MF
Cell cycle (Georgetown, Tex.) 2008 Dec;7(23):3737-46
Cell cycle (Georgetown, Tex.) 2008 Dec;7(23):3737-46
EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice.
Torchia EC, Boyd K, Rehg JE, Qu C, Baker SJ
Molecular and cellular biology 2007 Nov;27(22):7918-34
Molecular and cellular biology 2007 Nov;27(22):7918-34
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of NIH 3T3 cell lysates using Zymed Ms anti-p18 (INK4c) (Product # 39-3400).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of NIH 3T3 cell lysates using Zymed Ms anti-p18 (INK4c) (Product # 39-3400).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Indirect immunofluorescent staining of NIH 3T3 cells uninfected (left) or infected with MSCV-Ink4c-IRESGFP using Zymed Ms anti-p18 (INK4c) (Product # 39-3400). Image courtesy of Antoine Forget and Martine Roussel, St. Jude Children's Research Hospital, Memphis, TN.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 3 Evaluation of the effects of p25-GFP overexpression on cell cycle protein expression in malignant versus benign mouse MTC Immunoblots of lysates from proliferating malignant (P) and arrested benign (A) mouse MTC for A ) CDK2, CDK4 and CDK6; B ) cyclins A1, B1, D1, E2 and C ) p15 INK4b , p16 INK4a , p18 INK4c , p19 INK4d , p21 CIP/WAF1 and p27 KIP . P-values are p < 0.0001 for CDK2, p = 0.6974 for CDK4, p = 0.0633 for CDK6; p < 0.0001 for cyclin-A1, p = 0.0194 for cyclin-B1, p = 0.3416 for cyclin-D1, p < 0.0001 for cyclin-E2; p = 0.0002 for p15 INK4b , p = 0.291 for p16 INK4a , p = 0.0006 for p18 INK4c , p = 0.0054 for p19 INK4d , p = 0.02 for p21 CIP/WAF and p = 0.67 for p27 KIP1 . Data are represented as mean +/- SEM, N = 6 for each condition.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 Evaluation of the effect of CDK5 activity on cell cycle protein expression in human MTC cells Immunoblots of lysates from MTC-SK cells transfected with either a control plasmid (Con) or a kinase-dead (Kd) CDK5 encoding plasmid for A ) CDK2, CDK4 and CDK6; B ) cyclin-A1,-B1,-E2 and C ) p15 INK4b , p16 INK4a , p18 INK4c , p19 INK4d , p21 CIP/WAF1 and p27 KIP . P-values are p = 0.0244 for CDK2, p = 0.038 for CDK4, p = 0.009 for CDK6; p < 0.0001 for cyclin-A1, p = 0.0005 for cyclin-B1, p = 0.0116 for cyclin-E2; p = 0.0044 for p15 INK4b , p = 0.4687 for p16 INK4a , p = 0.1032 for p18 INK4c , p = 0.0195 for p19 INK4d , p = 0.0022 for p21 CIP/WAF and p = 0.2674 for p27 KIP1 . Data are represented as mean +/- SEM, N = 4-6 for each condition.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5 Analysis of cell cycle protein expression in human MTC samples Representative immunoblots of lysates from control thyroid tissue (Co), sporadic (Sp) and hereditary (H) human MTC tumors with antibodies as indicated are shown with quantification. Protein levels were normalized to Coomassie blue (CB) signal. Immunoblots were probed with antibodies to A ) CDK2, CDK4 and CDK6; B ) cyclins-A1, -D1, -E2; C ) in p15 INK4b , p16 INK4a , p18 INK4c , p19 INK4d , p21 CIP/WAF1 and p27 KIP . P-values were for CDK2, Sp, p = 0.0168 and H, p = 0.0140; for CDK4, Sp, p = 0.4072 and H, p = 0.8576; for CDK6, Sp, p = 0.5484 and H, p = 0.4916; for cyclin-A1, Sp, p = 0.9923 and H, p = 0.7017; for cyclin-D1, Sp, p = 0.0307 and H, p = 0.6883; for cyclin-E2, Sp, p = 0.2645 and H, p = 0.3070; for p15 INK4b , Sp, p = 0.0088 and H, p = 0.0310; for p16 INK4a , Sp, p = 0.0014 and H, p = 0.0496; for p18 INK4c , Sp, p = 0.0309 and H, p = 0.1054; for p19 INK4d , Sp, p = 0.0484 and H, p = 0.3560; for p21 CIP/WAF , Sp, p = 0.0554 and H, p = 0.6807; for p27 KIP1 , Sp, p = 0.2149 and H, p = 0.2131. Data are represented as mean +/- SEM, N = 4 for each condition.
